Mycoplasma genitalium is a common sexually transmissible pathogen that causes urethritis and cervicitis with symptoms and signs similar to Chlamydia trachomatis infection.
treatments are presented in Table 1 . Because of symptoms and signs of a perineal abscess with an anal fistula he had surgery and was treated with imipenem/cilastatin. Retrospectively, lymphogranuloma venereum was assumed to be the cause of the anal symptoms; however, this was not suspected or tested for initially. Consequently, 4 months later, treatment with doxycycline (100 mg twice daily for 14 days) was prescribed. However, a rectal test for C. trachomatis was negative.
A first void urine (FVU) PCR test, 6 months after the first M. genitaliumpositive test, analysed at the Statens Serum Institut (SSI), Copenhagen, was M. genitalium-positive with a mutation in region V of the 23SrRNA gene (A2058T). He was then treated with pristinamycin (1 g three times daily for 10 days) without clearance. His partner living and tested abroad was M. genitalium-negative according to the patient.
During the following year the patient experienced weight loss, fatigue and chronic herpes simplex virus type 2 anogenital ulcers. Eventually he decided to be tested for HIV infection (which he had declined to do earlier) and he was diagnosed with AIDS. Antiretroviral treatment as well as treatment with trimethoprim/sulfamethoxazole was initiated. He gained weight, is currently well and with undetectable HIV-1 RNA.
Owing to a positive syphilis antibody test, treatment with doxycycline for 30 days was prescribed. FVU tests for M. genitalium were repeatedly positive. A urine sample analysed at the SSI 17 months after the first known positive test, showed persisting macrolide resistance now with both A2058G and A2058T mutations present. However, MgPa typing revealed only one strain with the same strain type as initially.
Despite being asymptomatic, the patient was highly motivated to undergo treatment. This was 2 years after the first verified positive test. Spectinomycin, an aminocyclitol aminoglycoside, only used as an alternative treatment for N. gonorrhoeae, is theoretically active against M. genitalium and a single experiment showing an MIC of 4 mg/L for the macrolide susceptible G37 type strain of M. genitalium supported its use (J. S. Jensen, unpublished data). Spectinomycin hydrochloride (Trobicin V R ) (2 g) was administrated intramuscularly once daily for 7 days. An FVU test taken on the first treatment day was an M. genitalium-positive A2058G mutation. FVU samples were collected by the patient on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26 and sent by post weekly to the SSI for analysis as previously described.
9 From the fourth day of treatment all samples were negative for M. genitalium. No adverse events were reported. This is the first known report of spectinomycin treatment against M. genitalium. An extended treatment regimen was used because of lack of previous experience and the known slow replication rate of M. genitalium. The rapid response with negative tests in this patient is in line with a treatment study with azithromycin and moxifloxacin. 9 In that study a late occurrence (after 2-3 weeks) of resistant M. genitalium strains occurred in a few cases.
9 A late follow-up at 65 days after treatment was M. genitaliumpositive (FVU). Fifty days after treatment, the patient had unprotected sexual intercourse with his partner living abroad, who had neither been tested nor treated for M. genitalium. Thus, reinfection was highly likely. Future studies are needed to determine whether a shorter treatment period would be sufficient.
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